{"id":717,"date":"2016-11-16T17:00:25","date_gmt":"2016-11-16T16:00:25","guid":{"rendered":"http:\/\/www.nanexa.com\/nanexa-delarsrapport-januari-september-2016\/"},"modified":"2017-06-16T09:02:15","modified_gmt":"2017-06-16T07:02:15","slug":"nanexa-delarsrapport-januari-september-2016","status":"publish","type":"post","link":"https:\/\/nanexa.com\/sv\/nanexa-delarsrapport-januari-september-2016\/","title":{"rendered":"Nanexa: Del\u00e5rsrapport januari &#8211; september 2016"},"content":{"rendered":"<p style=\"font-family: arial,helvetica,sans-serif;\"><span style=\"font-size: 10pt;\"><strong>Sammanfattning av rapportperioden 1 januari \u2013 30 september 2016<\/strong><\/span><\/p>\n<ul style=\"font-family: arial,helvetica,sans-serif;\">\n<li><span style=\"font-size: 10pt;\">Oms\u00e4ttningen uppgick till: 280 (346) KSEK<\/span><\/li>\n<li><span style=\"font-size: 10pt;\">R\u00f6relseresultatet (EBIT) uppgick till: &#8211; 4 226 (-2 444) KSEK<\/span><\/li>\n<li><span style=\"font-size: 10pt;\">Resultatet efter skatt uppgick till: &#8211; 4 263 (-2 552) KSEK<\/span><\/li>\n<li><span style=\"font-size: 10pt;\">Resultat per aktie uppgick till: -0,71 (-0,94) SEK<\/span><\/li>\n<li><span style=\"font-size: 10pt;\">Periodens kassafl\u00f6de uppgick till: 11 817 (4 820) KSEK<\/span><\/li>\n<\/ul>\n<p style=\"font-family: arial,helvetica,sans-serif;\"><span style=\"font-size: 10pt;\"><strong>Sammanfattning av rapportperioden 1 juli \u2013 30 september 2016<\/strong><\/span><\/p>\n<ul style=\"font-family: arial,helvetica,sans-serif;\">\n<li><span style=\"font-size: 10pt;\">Oms\u00e4ttningen uppgick till: 105 (0) KSEK<\/span><\/li>\n<li><span style=\"font-size: 10pt;\">R\u00f6relseresultatet (EBIT) uppgick till: &#8211; 1 337 (-1 100) KSEK<\/span><\/li>\n<li><span style=\"font-size: 10pt;\">Resultatet efter skatt uppgick till: &#8211; 1 343 (-1 112) KSEK<\/span><\/li>\n<li><span style=\"font-size: 10pt;\">Resultat per aktie uppgick till: -0,18 (-0,22) SEK<\/span><\/li>\n<li><span style=\"font-size: 10pt;\">Periodens kassafl\u00f6de uppgick till: \u00a0&#8211; 3 970 (- 2 085) KSEK<\/span><\/li>\n<\/ul>\n<p style=\"font-family: arial,helvetica,sans-serif;\"><span style=\"font-size: 10pt;\"><strong>V\u00e4sentliga h\u00e4ndelser under perioden <\/strong>\u00a0<\/span><\/p>\n<ul style=\"font-family: arial,helvetica,sans-serif;\">\n<li><span style=\"font-size: 10pt;\">Nanexa har beviljats ett tillv\u00e4xtl\u00e5n fr\u00e5n ALMI om 5,7 MSEK<\/span><\/li>\n<li><span style=\"font-size: 10pt;\">Nanexa har lagt en order p\u00e5 en ALD (Atomic Layer Deposition) processutrustning i pilotskala.<\/span><\/li>\n<li><span style=\"font-size: 10pt;\">Nanexa har deltagit p\u00e5 NLS dagarna i Stockholm 14-15 september och d\u00e4r knutit kontakt med potentiella samarbetspartners och licenstagare f\u00f6r vidare verifiering och utveckling av bolagets PharmaShell\u00ae.<\/span><\/li>\n<\/ul>\n<p style=\"font-family: arial,helvetica,sans-serif;\"><span style=\"font-size: 10pt;\"><strong>V\u00e4sentliga h\u00e4ndelser efter periodens utg\u00e5ng<\/strong><\/span><\/p>\n<ul style=\"font-family: arial,helvetica,sans-serif;\">\n<li><span style=\"font-size: 10pt;\"><strong> <\/strong>Nanexa har anst\u00e4llt Joel Hellrup, doktor i farmaci fr\u00e5n Uppsala universitet med start den 1\/10.<\/span><\/li>\n<\/ul>\n<p style=\"font-family: arial,helvetica,sans-serif;\"><span style=\"font-size: 10pt;\"><strong>VD-Kommentar<\/strong><\/span><\/p>\n<p style=\"font-family: arial,helvetica,sans-serif;\"><span style=\"font-size: 10pt;\">Under Nordic Life Science (NLS) dagarna i Stockholm i mitten av september fick vi \u00e5terigen tillf\u00e4lle att tr\u00e4ffa de stora l\u00e4kemedelsbolagen och intressanta nichf\u00f6retag inom l\u00e4kemedelsbranschen och presentera f\u00f6retagets unika nanobaserade drug deliveryplattform PharmaShell\u00ae. Det \u00e4r tydligt att det finns ett stort intresse och nyfikenhet kring den patenterade teknologiplattformen och de unika egenskaper den har. Bland annat att PharmaShell\u00ae skapar en m\u00f6jlighet att utveckla s.k. dep\u00e5beredningar, m\u00f6jligheten att bel\u00e4gga nanopartiklar av l\u00e4kemedelssubstans med PharmaShell\u00ae samt m\u00f6jligheten att koppla antikroppar till PharmaShell\u00ae. Detta b\u00e5de f\u00f6r att anv\u00e4ndas i en s.k. \u201dLife Cycle Management\u201d strategi f\u00f6r redan marknadsf\u00f6rda produkter samt f\u00f6r helt nya l\u00e4kemedelssubstanser. De samtal vi haft under dessa dagar konfirmerar ocks\u00e5 att v\u00e5r fastst\u00e4llda utvecklingsplan ligger i linje med vad de stora l\u00e4kemedelsbolagen f\u00f6rv\u00e4ntar sig vilket ger ett kvitto p\u00e5 att vi t\u00e4nker r\u00e4tt. Jag ser det som viktigt att vi f\u00e5r \u00e5terkoppling av vilka m\u00f6jligheter l\u00e4kemedelsbolagen ser och vilka behov de har. Viktigt ocks\u00e5 att vi p\u00e5b\u00f6rjat en dialog med ett st\u00f6rre antal f\u00f6retag redan nu med sikte p\u00e5 kommande kommersiella licensavtal.<\/span><\/p>\n<p style=\"font-family: arial,helvetica,sans-serif;\"><span style=\"font-size: 10pt;\">Vi har under perioden tagit flera steg f\u00f6r att skapa ytterligare kapacitet i f\u00f6retaget.<\/span><\/p>\n<p style=\"font-family: arial,helvetica,sans-serif;\"><span style=\"font-size: 10pt;\">Till att b\u00f6rja med har vi nu anst\u00e4llt Joel Hellrup, doktor i farmaci, som f\u00f6rst\u00e4rker v\u00e5r utvecklingsgrupp med specifik kompetens inom l\u00e4kemedelsutveckling. Vi har ocks\u00e5 p\u00e5b\u00f6rjat ytterligare rekryteringar f\u00f6r att bredda kompetensen och \u00f6ka kapaciteten i gruppen. Jag \u00e4r ocks\u00e5 glad \u00f6ver att vi beviljats ett tillv\u00e4xtl\u00e5n fr\u00e5n ALMI om 5,7 MSek med f\u00f6rdelaktiga villkor s\u00e5som en l\u00e4ngre amorteringsfrihet och en l\u00f6ptid upp till 10 \u00e5r. Detta m\u00f6jligg\u00f6r att vi nu kan investera i kritisk utrustning och redan under september m\u00e5nad lade vi en order p\u00e5 en st\u00f6rre och mer avancerad Atomic Layer Deposition (ALD) reaktor. Den kommer levereras under Q1, 2017 och skapar d\u00e5 m\u00f6jlighet f\u00f6r oss att skala upp PharmaShell\u00ae processen samt att arbeta parallellt med flera olika utvecklingsprojekt. Tillv\u00e4xtl\u00e5net ger oss ocks\u00e5 m\u00f6jlighet att investera i ytterligare viktig utrustning och dessa investeringar har p\u00e5b\u00f6rjats.<\/span><\/p>\n<p style=\"font-family: arial,helvetica,sans-serif;\"><span style=\"font-size: 10pt;\">I utvecklingen arbetar vi bland annat vidare med den titandioxid baserade PharmaShell\u00ae processen som uppvisar v\u00e4ldigt intressanta egenskaper. V\u00e5rt samarbete med AstraZeneca fortl\u00f6per och i v\u00e5rt samarbete skapas intressanta resultat som tar oss fram\u00e5t i utvecklingen. Vi arbetar ocks\u00e5 vidare f\u00f6r att ta fram ytterligare in-vitro och in-vivo data med sikte p\u00e5 f\u00f6rdjupade diskussioner med de stora l\u00e4kemedelsbolagen.<\/span><\/p>\n<p style=\"font-family: arial,helvetica,sans-serif;\"><span style=\"font-size: 10pt;\">David Westberg, VD<\/span><\/p>\n<p style=\"font-family: arial,helvetica,sans-serif;\"><strong><span style=\"font-size: 10pt;\">Kommentarer till resultatet<br \/><\/span><\/strong><span style=\"font-size: 10pt;\">Vi kan konstatera att det ekonomiska utfallet f\u00f6ljer budget samt att den l\u00e5ngsiktiga finansieringen \u00e4r p\u00e5 plats, vilket \u00e4r tillfredsst\u00e4llande.<\/span><\/p>\n<p style=\"font-family: arial,helvetica,sans-serif;\"><strong><span style=\"font-size: 10pt;\">Aktien<br \/><\/span><\/strong><span style=\"font-size: 10pt;\">Nanexa AB (publ) noterades p\u00e5 Aktietorget den 17 juni, 2015.<\/span><\/p>\n<p style=\"font-family: arial,helvetica,sans-serif;\"><span style=\"font-size: 10pt;\"><strong>Resultat per aktie<\/strong>\u00a0\u00a0<br \/><\/span><span style=\"font-size: 10pt;\">Resultat per aktie f\u00f6r det tredje kvartalet uppgick till -0,18 (-0,22) SEK och f\u00f6r perioden 1 januari \u2013 <\/span><span style=\"font-size: 10pt;\">30 september 2016 till -0,71 (-0,94) SEK.<\/span><\/p>\n<p style=\"font-family: arial,helvetica,sans-serif;\"><strong><span style=\"font-size: 10pt;\">Antalet aktier<br \/><\/span><\/strong><span style=\"font-size: 10pt;\">Nanexa AB (publ) har per 2016-09-30, 7 625 054 stycken utest\u00e5ende aktier med ett kvotv\u00e4rde om 0,13 SEK.<\/span><\/p>\n<p style=\"font-family: arial,helvetica,sans-serif;\"><span style=\"font-size: 10pt;\"><strong>Principer f\u00f6r rapportens uppr\u00e4ttande<\/strong> <br \/><\/span><span style=\"font-size: 10pt;\">Del\u00e5rsrapporten har uppr\u00e4ttats enligt samma redovisningsprinciper som i bolagets senaste \u00e5rsredovisning, det vill s\u00e4ga enligt \u00c5rsredovisningslagen och Bokf\u00f6ringsn\u00e4mndens allm\u00e4nna r\u00e5d BFNAR 2012:1 \u00c5rsredovisning och koncernredovisning (K3). <\/span><\/p>\n<p style=\"font-family: arial,helvetica,sans-serif;\"><strong><span style=\"font-size: 10pt;\">Kommande rapporttillf\u00e4llen<br \/><\/span><\/strong><span style=\"font-size: 10pt;\">Nanexa AB l\u00e4mnar \u00e5terkommande ekonomisk information enligt f\u00f6ljande plan. <br \/><\/span><span style=\"font-size: 10pt;\">Bolagets r\u00e4kenskaps\u00e5r \u00e4r 1 januari \u2013 31 december<\/span><\/p>\n<p style=\"font-family: arial,helvetica,sans-serif;\"><span style=\"font-size: 10pt;\"><\/span><span style=\"font-size: 10pt;\">Bokslutskommunik\u00e9 2016:\u00a015 februari, 2017<br \/><\/span><span style=\"font-size: 10pt;\">\u00c5rsredovisning 2016: 11 april, 2017<br \/><\/span><span style=\"font-size: 10pt;\">Q1 rapport\u00a0\u00a017 maj, 2017<br \/><\/span><span style=\"font-size: 10pt;\">Q2 rapport\u00a024 augusti, 2017<br \/><\/span><span style=\"font-size: 10pt;\">Q3 rapport\u00a017 november, 2017<\/span><\/p>\n<p style=\"font-family: arial,helvetica,sans-serif;\"><span style=\"font-size: 10pt;\">Denna del\u00e5rsrapport har inte varit f\u00f6rem\u00e5l f\u00f6r \u00f6versiktlig granskning av bolagets revisor.<\/span><\/p>\n<p style=\"font-family: arial,helvetica,sans-serif;\"><span style=\"font-size: 10pt;\"><strong>Nanexa AB (PUBL)<\/strong><\/span><\/p>\n<p style=\"font-family: arial,helvetica,sans-serif;\"><span style=\"font-size: 10pt;\">Nanexa AB \u00e4r ett h\u00f6gteknologiskt forskningsf\u00f6retag som utvecklar och marknadsf\u00f6r produkter inom nanoteknologi. Bolagets fokus ligger p\u00e5 PharmaShell\u00ae som \u00e4r ett nytt och banbrytande drug delivery system som bed\u00f6ms ha en stor potential inom ett flertal behandlingsomr\u00e5den. Inom ramen f\u00f6r PharmaShell\u00ae har Nanexa samarbetsavtal med bland andra AstraZeneca, Uppsala universitet och Karolinska Institutet.<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p style=\"font-family: arial,helvetica,sans-serif;\">Sammanfattning av rapportperioden 1 januari \u2013 30 september 2016<\/p>\n<ul style=\"font-family: arial,helvetica,sans-serif;\">\n<li>Oms\u00e4ttningen uppgick till: 280 (346) KSEK<\/li>\n<li>R\u00f6relseresultatet (EBIT) uppgick till: &#8211; 4 226 (-2 444) KSEK<\/li>\n<li>Resultatet efter skatt uppgick till: &#8211;<\/li>\n<\/ul>\n<p><a class=\"read-more\" href=\"https:\/\/nanexa.com\/sv\/nanexa-delarsrapport-januari-september-2016\/\">L\u00e4s mer<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[7],"tags":[],"class_list":["post-717","post","type-post","status-publish","format-standard","hentry","category-nyheter"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nanexa: Del\u00e5rsrapport januari - september 2016 - Nanexa AB<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanexa.com\/nanexa-delarsrapport-januari-september-2016\/\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanexa: Del\u00e5rsrapport januari - september 2016 - Nanexa AB\" \/>\n<meta property=\"og:description\" content=\"Sammanfattning av rapportperioden 1 januari \u2013 30 september 2016 Oms\u00e4ttningen uppgick till: 280 (346) KSEK R\u00f6relseresultatet (EBIT) uppgick till: &#8211; 4 226 (-2 444) KSEK Resultatet efter skatt uppgick till: &#8211;L\u00e4s mer\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanexa.com\/nanexa-delarsrapport-januari-september-2016\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanexa AB\" \/>\n<meta property=\"article:published_time\" content=\"2016-11-16T16:00:25+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2017-06-16T07:02:15+00:00\" \/>\n<meta name=\"author\" content=\"bastardreklam\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Skriven av\" \/>\n\t<meta name=\"twitter:data1\" content=\"bastardreklam\" \/>\n\t<meta name=\"twitter:label2\" content=\"Ber\u00e4knad l\u00e4stid\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minuter\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/nanexa-delarsrapport-januari-september-2016\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/nanexa-delarsrapport-januari-september-2016\\\/\"},\"author\":{\"name\":\"bastardreklam\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/person\\\/68861ce2615a32f1e9a8a421cd4e604d\"},\"headline\":\"Nanexa: Del\u00e5rsrapport januari &#8211; september 2016\",\"datePublished\":\"2016-11-16T16:00:25+00:00\",\"dateModified\":\"2017-06-16T07:02:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/nanexa-delarsrapport-januari-september-2016\\\/\"},\"wordCount\":858,\"publisher\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\"},\"articleSection\":[\"Nyheter\"],\"inLanguage\":\"sv-SE\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/nanexa-delarsrapport-januari-september-2016\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/nanexa-delarsrapport-januari-september-2016\\\/\",\"name\":\"Nanexa: Del\u00e5rsrapport januari - september 2016 - Nanexa AB\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\"},\"datePublished\":\"2016-11-16T16:00:25+00:00\",\"dateModified\":\"2017-06-16T07:02:15+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/nanexa-delarsrapport-januari-september-2016\\\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanexa.com\\\/nanexa-delarsrapport-januari-september-2016\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/nanexa-delarsrapport-januari-september-2016\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Hem\",\"item\":\"https:\\\/\\\/nanexa.com\\\/sv\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nanexa: Del\u00e5rsrapport januari &#8211; september 2016\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"name\":\"Nanexa AB\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanexa.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\",\"name\":\"Nanexa AB\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"sv-SE\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"contentUrl\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"width\":165,\"height\":50,\"caption\":\"Nanexa AB\"},\"image\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/person\\\/68861ce2615a32f1e9a8a421cd4e604d\",\"name\":\"bastardreklam\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"sv-SE\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/62836a2290061bb860a6ef73affdbedf9d7377d872b392c7b91b47027427a5db?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/62836a2290061bb860a6ef73affdbedf9d7377d872b392c7b91b47027427a5db?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/62836a2290061bb860a6ef73affdbedf9d7377d872b392c7b91b47027427a5db?s=96&d=mm&r=g\",\"caption\":\"bastardreklam\"},\"url\":\"https:\\\/\\\/nanexa.com\\\/sv\\\/author\\\/bastardreklam\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nanexa: Del\u00e5rsrapport januari - september 2016 - Nanexa AB","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanexa.com\/nanexa-delarsrapport-januari-september-2016\/","og_locale":"sv_SE","og_type":"article","og_title":"Nanexa: Del\u00e5rsrapport januari - september 2016 - Nanexa AB","og_description":"Sammanfattning av rapportperioden 1 januari \u2013 30 september 2016 Oms\u00e4ttningen uppgick till: 280 (346) KSEK R\u00f6relseresultatet (EBIT) uppgick till: &#8211; 4 226 (-2 444) KSEK Resultatet efter skatt uppgick till: &#8211;L\u00e4s mer","og_url":"https:\/\/nanexa.com\/nanexa-delarsrapport-januari-september-2016\/","og_site_name":"Nanexa AB","article_published_time":"2016-11-16T16:00:25+00:00","article_modified_time":"2017-06-16T07:02:15+00:00","author":"bastardreklam","twitter_card":"summary_large_image","twitter_misc":{"Skriven av":"bastardreklam","Ber\u00e4knad l\u00e4stid":"4 minuter"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nanexa.com\/nanexa-delarsrapport-januari-september-2016\/#article","isPartOf":{"@id":"https:\/\/nanexa.com\/nanexa-delarsrapport-januari-september-2016\/"},"author":{"name":"bastardreklam","@id":"https:\/\/nanexa.com\/#\/schema\/person\/68861ce2615a32f1e9a8a421cd4e604d"},"headline":"Nanexa: Del\u00e5rsrapport januari &#8211; september 2016","datePublished":"2016-11-16T16:00:25+00:00","dateModified":"2017-06-16T07:02:15+00:00","mainEntityOfPage":{"@id":"https:\/\/nanexa.com\/nanexa-delarsrapport-januari-september-2016\/"},"wordCount":858,"publisher":{"@id":"https:\/\/nanexa.com\/#organization"},"articleSection":["Nyheter"],"inLanguage":"sv-SE"},{"@type":"WebPage","@id":"https:\/\/nanexa.com\/nanexa-delarsrapport-januari-september-2016\/","url":"https:\/\/nanexa.com\/nanexa-delarsrapport-januari-september-2016\/","name":"Nanexa: Del\u00e5rsrapport januari - september 2016 - Nanexa AB","isPartOf":{"@id":"https:\/\/nanexa.com\/#website"},"datePublished":"2016-11-16T16:00:25+00:00","dateModified":"2017-06-16T07:02:15+00:00","breadcrumb":{"@id":"https:\/\/nanexa.com\/nanexa-delarsrapport-januari-september-2016\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanexa.com\/nanexa-delarsrapport-januari-september-2016\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/nanexa.com\/nanexa-delarsrapport-januari-september-2016\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Hem","item":"https:\/\/nanexa.com\/sv\/"},{"@type":"ListItem","position":2,"name":"Nanexa: Del\u00e5rsrapport januari &#8211; september 2016"}]},{"@type":"WebSite","@id":"https:\/\/nanexa.com\/#website","url":"https:\/\/nanexa.com\/","name":"Nanexa AB","description":"","publisher":{"@id":"https:\/\/nanexa.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanexa.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"},{"@type":"Organization","@id":"https:\/\/nanexa.com\/#organization","name":"Nanexa AB","url":"https:\/\/nanexa.com\/","logo":{"@type":"ImageObject","inLanguage":"sv-SE","@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","contentUrl":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","width":165,"height":50,"caption":"Nanexa AB"},"image":{"@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/nanexa.com\/#\/schema\/person\/68861ce2615a32f1e9a8a421cd4e604d","name":"bastardreklam","image":{"@type":"ImageObject","inLanguage":"sv-SE","@id":"https:\/\/secure.gravatar.com\/avatar\/62836a2290061bb860a6ef73affdbedf9d7377d872b392c7b91b47027427a5db?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/62836a2290061bb860a6ef73affdbedf9d7377d872b392c7b91b47027427a5db?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/62836a2290061bb860a6ef73affdbedf9d7377d872b392c7b91b47027427a5db?s=96&d=mm&r=g","caption":"bastardreklam"},"url":"https:\/\/nanexa.com\/sv\/author\/bastardreklam\/"}]}},"_links":{"self":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/posts\/717","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/comments?post=717"}],"version-history":[{"count":1,"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/posts\/717\/revisions"}],"predecessor-version":[{"id":728,"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/posts\/717\/revisions\/728"}],"wp:attachment":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/media?parent=717"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/categories?post=717"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/tags?post=717"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}